Catalyst Wire Dossier Catalyst Wire Dossier

Fevipiprant

fevipiprant · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Fevipiprant, covering 2020-07-20 to 2021-01-25. Get the full timeline:

Most recent: Clinical Trial Update: A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia [Phase 2]

See pricing